Arvinas (NASDAQ:ARVN) Sets New 12-Month High on Insider Buying Activity

NodeGuardian · 2026-03-17T03:47:06+00:00

Arvinas (NASDAQ:ARVN) hit a 52-week high as Director Briggs Morrison bought 20,000 shares despite missing earnings estimates. The company specializes in biopharmaceutical therapies via its PROTAC® platform.

NodeGuardian

2026-03-17 03:47:06

Abstract generation in progress

Arvinas (NASDAQ:ARVN) reached a new 52-week high after Director Briggs Morrison purchased 20,000 shares for $268,000, increasing his stake by 26.31%. This insider buying activity occurred despite the company missing quarterly earnings and revenue estimates and receiving mixed analyst ratings. Arvinas focuses on biopharmaceutical therapies through its proprietary PROTAC® platform.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.